IAVI searchers for presidential successor as McGlynn steps down
McGlynn began her tenure in July 2011, one year after she joined the board of directors in July 2010. She now plans to focus her energy and time on other interests, such as a foundation for rare diseases that she established in 2009. McGlynn will continue to assist and support the board through this transition.
“Margie’s outstanding experience as head of Merck global vaccines and her unique blend of professionalism and dedication have strongly positioned IAVI to provide continued innovation and value to the field of AIDS vaccine research and development,” IAVI Board Chair Alex Coutinho said. “The board is working diligently to identify the best person to lead IAVI’s next chapter.”
McGlynn's duties will not end until July 1, at the earliest.
“It has been a tremendous privilege to lead IAVI and to work alongside many of the world’s most committed AIDS vaccine researchers, advocates and donors,” McGlynn said. “The efforts of IAVI’s talented and dedicated Board, management and staff are augmented by those of an equally impressive group of partners and supporters. Together, we will achieve a world without AIDS.”